melanocyte lineage-specific antigen gp100

25  relevant articles (0 outcomes, 4 trials/studies) found for this Bio-Agent

288-Val-HLA-A*0201-associated gp100; ALLAVGATK; G280-9V peptide; G9-209-2M protein, human; HLA-A*0201-associated gp100 (280-288), Val(288)-; HLA-A*0201-associated gp100 (280-288), valyl(288)-; ME20 antigen; ME20 antigen, human; ME20 protein, human; ME20-M protein, human; ME20-S protein, human; MLSA gp100; Melanocyte protein mel 17, human; PMEL17 protein, human; Pmel 17 protein, human; Pmel17 protein, mouse; SILV protein, human; Si protein, mouse; Tyr-Leu-Glu-Pro-Gly-Pro-Val-Thr-Ala; YLEPGPVTA; alanyl-leucyl-leucyl-alanyl-valyl-glycyl-alanyl-threonyl-lysine; g209-217 protein, human; g209-2M protein, human; gp100 melanoma-associated antigen; gp100 melanoma-associated antigen (209-217), human; gp100(17-25) peptide; gp87 protein, mouse; melanocyte antigen gp87, mouse; melanoma antigen glycoprotein 100; melanoma peptide antigen gp100((209-217)), human; melanoma-associated antigen gp100; silver homolog (mouse) protein, human; silver locus protein, mouse; silver protein, mouse; tyrosyl-leucyl-glutamyl-prolyl-glycyl-prolyl-valyl-threonyl-alanine

Bio-Agent Context: Research Results

Experts

1.	Stowell, Christopher P: 1 article (11/2005)
2.	Eapen, Sara G: 1 article (11/2005)
3.	Hodi, F Stephen: 1 article (11/2005)
4.	Rubin, Krista M: 1 article (11/2005)
5.	Jonasch, Eric P: 1 article (11/2005)
6.	Daley, Heather: 1 article (11/2005)
7.	Webb, Iain J: 1 article (11/2005)
8.	Fee, Sharon V: 1 article (11/2005)
9.	Soiffer, Robert J: 1 article (11/2005)
10.	Linette, Gerald P: 1 article (11/2005)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 11/01/2005 - "CONCLUSION: The high rate of immunization as measured by three independent assays and the occurrence of clinical regression support continued investigation of G280-9V peptide as a candidate epitope in melanoma vaccine formulations." 05/05/1999 - "As a model system, we used SCID mice bearing an s.c.-implanted human melanoma line (BLM-gp100) and in vitro-generated CTL specific for the gp100-derived immunogenic peptide YLEPGPVTA, which were injected i.v. with delay" 04/01/1998 - "To further evaluate its immunogenicity, ALLAVGATK was used to stimulate PBL derived from six additional HLA-A3.1 melanoma patients and seven healthy donors" 04/01/1998 - "The role of the ALLAVGATK peptide in the systemic immune response to melanoma of this patient was evaluated" 04/01/1998 - "Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 06/15/1998 - "Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection." 04/01/1998 - "When pulsed on the autologous peripheral blood mononuclear cells, the ALLAVGATK peptide generated tumor-specific HLA-A3-restricted T lymphocytes and a single restimulation in vitro was sufficient to raise gp100-specific T lymphocytes, indicating a high frequency of epitope-specific T cells" 04/01/1998 - "By transfection of a tumor cDNA library and in vitro sensitization experiments, the ALLAVGATK gp100/Mel17-derived peptide was found to be the epitope recognized by this melanoma-specific T cell line" 03/17/2004 - "Degradation of the tumor antigen epitope gp100(280-288) (YLEPGPVTA) was investigated in the presence of cultured human fibroblasts, and acellular supernatants obtained from these cells; the possible effect of substrate degradation on in vitro immunorecognition was also addressed" 03/01/2003 - "The possible degradation of the tumor antigen epitope gp100(280-288) (YLEPGPVTA) in the presence of the monocyte-like line U937, and the effect of degradation on the in vitro-measured immune recognition, were investigated by chromatographic techniques and immunological assays" Get all the results and reference details, order at left...
3.	Experimental Melanoma 05/01/2002 - "In this study, Lptn and/or melanoma-associated antigen gp100 were transfected into mouse bone marrow-derived DC, which were used as vaccines in B16 melanoma model" 09/01/2003 - "To improve the antitumor effect of DC vaccine, Th1-biasing cytokine interleukin (IL) 18 and melanoma-associated antigen gp100 were cotransfected into bone marrow-derived DC (IL-18/gp100-DC), which were used as vaccine to induce the protective and therapeutic immunity in a B16 melanoma model" Get all the results and reference details, order at left...
4.	Shock 05/15/2003 - "This report defines a novel approach to heat shock protein vaccine formulation that takes advantage of the chaperoning property of heat shock protein hsp110 to efficiently bind a large protein substrate (specifically, human melanoma-associated antigen gp100) during heat shock" Get all the results and reference details, order at left...
4 Diseases and 25 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Peptides
2.	HLA-A2 Antigen (HLA A2 Antigen)
3.	Vaccines
4.	Tetanus Toxoid (Vaccine, Tetanus)
5.	incomplete Freund's adjuvant
6.	HLA-A3 Antigen (HLA A3 Antigen)
7.	melanocyte lineage-specific antigen gp100
8.	Monophenol Monooxygenase (Tyrosinase)
9.	Antigens
10.	Epitopes
21 Drugs and Important Bio-Agents and 20 more articles analyzed in the Research Interface, order at left...